A trial looking at crizotinib for advanced cancer (CREATE)

Overview

Cancer types:

Blood cancers, High grade lymphoma, Kidney cancer, Lymphoma, Non-Hodgkin lymphoma (NHL), Renal cell cancer, Sarcoma, Secondary cancers, Soft tissue sarcoma

Status:

Results

Phase:

Phase 2

Details

This trial looked at crizotinib for people who had certain types of advanced cancer. And who might have changes to genes called ALK or MET.

It was for people whose cancer had grown into surrounding tissues or spread elsewhere in the body. This is locally advanced or metastatic cancer. It was for people who had no available to them.

This trial was open for people to join between 2013 and 2017. The trial team published several papers in 2017 and 2018. They published some further results in 2021.

Recruitment start: 1 July 2013

Recruitment end: 4 July 2017